BioXcel Therapeutics IncNASDAQ:BTAINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5848
- TODAY'S CHANGE (%)0.0347 (6.3079%)
- Bid / Lots0.5700/ 50
- Ask / Lots0.5900/ 4
- Open / Previous Close0.5500 / 0.5501
- Day Range
- 52 Week Range
- Volume466,149
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BTAI |
|---|---|---|
| 09:32 ET | 1020 | 0.5573 |
| 09:34 ET | 1700 | 0.5573 |
| 09:38 ET | 3600 | 0.57 |
| 09:39 ET | 1800 | 0.57 |
| 09:41 ET | 2100 | 0.57 |
| 09:45 ET | 1519 | 0.577 |
| 09:48 ET | 10800 | 0.578 |
| 09:50 ET | 200 | 0.570301 |
| 09:52 ET | 100 | 0.5702 |
| 09:54 ET | 101 | 0.5703 |
| 09:56 ET | 500 | 0.5731 |
| 09:57 ET | 2153 | 0.576 |
| 10:03 ET | 250 | 0.575536 |
| 10:08 ET | 850 | 0.576 |
| 10:10 ET | 10493 | 0.5795 |
| 10:12 ET | 3500 | 0.58 |
| 10:14 ET | 946 | 0.58 |
| 10:17 ET | 3296 | 0.58 |
| 10:19 ET | 1300 | 0.58 |
| 10:21 ET | 1599 | 0.5785 |
| 10:24 ET | 200 | 0.5805 |
| 10:26 ET | 600 | 0.580999 |
| 10:28 ET | 100 | 0.581 |
| 10:30 ET | 72430 | 0.58 |
| 10:32 ET | 4425 | 0.5737 |
| 10:33 ET | 201 | 0.5737 |
| 10:46 ET | 400 | 0.5704 |
| 10:51 ET | 1814 | 0.5702 |
| 10:53 ET | 100 | 0.5702 |
| 11:02 ET | 34499 | 0.57 |
| 11:04 ET | 334 | 0.571 |
| 11:08 ET | 1300 | 0.5737 |
| 11:09 ET | 1000 | 0.5785 |
| 11:11 ET | 2901 | 0.5789 |
| 11:13 ET | 560 | 0.579 |
| 11:15 ET | 1500 | 0.5746 |
| 11:20 ET | 300 | 0.5712 |
| 11:29 ET | 362 | 0.573 |
| 11:31 ET | 4650 | 0.570477 |
| 11:33 ET | 1100 | 0.573 |
| 11:36 ET | 193 | 0.57485 |
| 11:38 ET | 7134 | 0.581 |
| 11:40 ET | 600 | 0.579 |
| 11:44 ET | 2449 | 0.5812 |
| 11:47 ET | 150 | 0.5811 |
| 11:49 ET | 1800 | 0.583 |
| 11:51 ET | 160 | 0.5793 |
| 11:54 ET | 2086 | 0.5792 |
| 12:02 ET | 5768 | 0.5835 |
| 12:03 ET | 100 | 0.58 |
| 12:05 ET | 300 | 0.5817 |
| 12:07 ET | 5121 | 0.5835 |
| 12:09 ET | 5366 | 0.5834 |
| 12:12 ET | 10000 | 0.5801 |
| 12:16 ET | 1000 | 0.5803 |
| 12:18 ET | 3135 | 0.581 |
| 12:20 ET | 1750 | 0.582 |
| 12:21 ET | 300 | 0.5831 |
| 12:25 ET | 100 | 0.5831 |
| 12:32 ET | 100 | 0.5805 |
| 12:36 ET | 378 | 0.5808 |
| 12:38 ET | 1300 | 0.5806 |
| 12:39 ET | 619 | 0.5808 |
| 12:43 ET | 2520 | 0.585 |
| 12:45 ET | 1300 | 0.585 |
| 12:50 ET | 1964 | 0.585 |
| 12:56 ET | 600 | 0.585 |
| 12:57 ET | 3360 | 0.584 |
| 01:03 ET | 1680 | 0.5843 |
| 01:06 ET | 2137 | 0.5812 |
| 01:14 ET | 1000 | 0.581301 |
| 01:19 ET | 100 | 0.5824 |
| 01:33 ET | 1100 | 0.5813 |
| 01:37 ET | 200 | 0.584 |
| 01:48 ET | 2200 | 0.5813 |
| 01:50 ET | 3418 | 0.5831 |
| 01:51 ET | 150 | 0.58215 |
| 01:55 ET | 1187 | 0.5843 |
| 01:57 ET | 2500 | 0.583 |
| 02:00 ET | 300 | 0.5837 |
| 02:06 ET | 400 | 0.583 |
| 02:13 ET | 100 | 0.584 |
| 02:15 ET | 100 | 0.5815 |
| 02:20 ET | 300 | 0.584 |
| 02:22 ET | 100 | 0.5815 |
| 02:24 ET | 100 | 0.5815 |
| 02:26 ET | 100 | 0.5815 |
| 02:27 ET | 200 | 0.5815 |
| 02:29 ET | 100 | 0.5831 |
| 02:31 ET | 103 | 0.5813 |
| 02:33 ET | 1903 | 0.584 |
| 02:36 ET | 6768 | 0.5855 |
| 02:38 ET | 6000 | 0.5857 |
| 02:42 ET | 400 | 0.586 |
| 02:45 ET | 2800 | 0.585395 |
| 02:49 ET | 6600 | 0.586 |
| 02:54 ET | 6748 | 0.5857 |
| 02:58 ET | 500 | 0.5859 |
| 03:00 ET | 4150 | 0.5892 |
| 03:02 ET | 400 | 0.591 |
| 03:05 ET | 400 | 0.5915 |
| 03:07 ET | 80465 | 0.5811 |
| 03:09 ET | 9000 | 0.5813 |
| 03:12 ET | 186 | 0.5853 |
| 03:20 ET | 300 | 0.581 |
| 03:30 ET | 719 | 0.5842 |
| 03:32 ET | 547 | 0.581 |
| 03:36 ET | 831 | 0.581 |
| 03:38 ET | 100 | 0.581 |
| 03:39 ET | 1549 | 0.5842 |
| 03:41 ET | 200 | 0.5854 |
| 03:45 ET | 100 | 0.5812 |
| 03:50 ET | 53215 | 0.5842 |
| 03:52 ET | 1200 | 0.5841 |
| 03:54 ET | 100 | 0.577 |
| 03:56 ET | 800 | 0.577 |
| 03:57 ET | 242 | 0.577 |
| 03:59 ET | 6131 | 0.5848 |
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 6, 2024
DJ BioXcel Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 7:45AM ET on Friday Sep 06, 2024 by Dow Jones
7:45AM ET on Friday Sep 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioXcel Therapeutics Inc | 23.8M | -0.2x | --- |
Cyclo Therapeutics Inc | 21.3M | -0.8x | --- |
KALA BIO Inc | 24.9M | -0.4x | --- |
DH Enchantment Inc | 23.0M | -30.0x | --- |
PolyPid Ltd | 25.2M | -0.4x | --- |
China Health Industries Holdings Inc | 21.3M | -15.6x | --- |
Company Information
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Contact Information
- Headquarters
- 555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107
- Phone
- 203-643-8060
- Fax
- 302-636-5454
Executives
- Lead Independent Chairman of the Board
- Peter Mueller
- President, Chief Executive Officer, Director
- Vimal Mehta
- Chief Financial Officer, Senior Vice President
- Richard Steinhart
- Executive Vice President, Chief Scientific Officer
- Frank Yocca
- Executive Vice President, Chief of Product Development and Medical Officer
- Vincent O'Neill
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.8M |
|---|---|
Revenue (TTM) | $2.4M |
Shares Outstanding | 40.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.30 |
EPS | $-3.56 |
Book Value | $-1.89 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 9.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,562.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
